Literature DB >> 16911982

Retinoblastoma: expression of HLA-G.

Mohan Adithi1, Mallikarjuna Kandalam, Hema L Ramkumar, Ayshwarya Subramanian, Nalini Venkatesan, Subramanian Krishnakumar.   

Abstract

PURPOSE: Human leukocyte antigen (HLA) mediates interactions of tumor cells with cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Retinoblastoma (RB) is the most common intraocular malignant tumor in childhood and is characterized by direct spread to the optic nerve and orbit as well as hematogenous and lymphatic spread. Earlier, we observed that invasive RB showed reduced HLA, which could contribute to its escape from the immune system. Little is known about the role of the nonclassical HLA molecule, HLA-G, in RB and its role in tumor escape mechanisms in RB.
METHODS: Forty archival paraffin-embedded RB tumors were analyzed for the expression of HLA-G by immunohistochemistry using a monoclonal antibody; fresh tumor samples were also subjected to Western blot analysis. There were 22 tumors with no invasion and 18 with invasion of the choroid/optic nerve. Immunoanalysis was performed based on the International Histocompatibility Working Group Project Description.
RESULTS: HLA-G was negative in the non-neoplastic retina, reduced in 22/22 tumors with no invasion, and positive in 15/18 with invasion. The immunohistochemistry results were confirmed by Western blot analysis. The difference in expression between the two groups was significant ( p < 0.001). There was no correlation of HLA-G expression with differentiation of the tumors.
CONCLUSION: Increased expression of HLA-G was observed in invasive RB. This preliminary observation deserves further investigation and may shed more light on the immune escape mechanisms of this tumor and thus enable novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16911982     DOI: 10.1080/09273940600826497

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  6 in total

1.  Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV).

Authors:  Marcia C M Guimarães; Christiane P Soares; Eduardo A Donadi; Sophie F M Derchain; Liliana A L A Andrade; Tarsia G A Silva; Marcela K Hassumi; Renata T Simões; Fabiana A Miranda; Régia C P Lira; Janaina Crispim; Edson G Soares
Journal:  J Histochem Cytochem       Date:  2009-09-28       Impact factor: 2.479

Review 2.  Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.

Authors:  Eduardo A Donadi; Erick C Castelli; Antonio Arnaiz-Villena; Michel Roger; Diego Rey; Philippe Moreau
Journal:  Cell Mol Life Sci       Date:  2010-11-24       Impact factor: 9.261

3.  A clinical update and radiologic review of pediatric orbital and ocular tumors.

Authors:  Ajay A Rao; John H Naheedy; James Y-Y Chen; Shira L Robbins; Hema L Ramkumar
Journal:  J Oncol       Date:  2013-03-12       Impact factor: 4.375

4.  Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.

Authors:  W-H Yan; A Lin; B-G Chen; W-D Luo; M-Z Dai; X-J Chen; H-H Xu; B-L Li
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

5.  Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.

Authors:  A Lin; H-X Chen; C-C Zhu; X Zhang; H-H Xu; J-G Zhang; Q Wang; W-J Zhou; W-H Yan
Journal:  J Cell Mol Med       Date:  2010-10-03       Impact factor: 5.310

Review 6.  HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies.

Authors:  Fabio Morandi; Irma Airoldi
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.